Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00338026 | A Phase I Study of ECO-4601 in Patients With Advanced Cancer | completed | Phase 1 | 26 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00715286 | Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study | unknown | Phase 3 | 180 | All India Institute of Medical SciencesOTHER | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00655447 |
| Examining the Long-Term Risks of Oophorectomy |
| completed |
| — |
| 32,175 |
| Parker, William H., M.D.OTHER |
| 1 |
| Apr 9, 2008 |
| clinicaltrials |
| NCT00001302 | A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 52 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001944 | Vinorelbine and XR9576 to Treat Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00006155 | SU5416 and Carboplatin to Treat Ovarian Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
| NCT00050375 | Clinical Trial for Ovarian Cancer (OvaRex®) | terminated | Phase 3 | 354 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00047632 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer | terminated | Phase 3 | 847 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00533299 | Hydralazine Valproate for Ovarian Cancer | unknown | Phase 3 | 211 | National Institute of CancerologíaOTHER_GOV | 1 | Sep 21, 2007 | clinicaltrials |
| NCT00527631 | Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer(OVAR-IMRT-01) | unknown | Phase 1 | 8 | Heidelberg UniversityOTHER | 1 | Sep 11, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00155935 | The Development of Human Immunologic Assays Specific to Folate Receptor Antigen | unknown | N/A | 50 | National Taiwan University HospitalOTHER | 1 | Aug 13, 2007 | clinicaltrials |
| NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 7 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00190697 | A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment | completed | Phase 4 | 70 | Eli Lilly and CompanyINDUSTRY | 1 | May 25, 2007 | clinicaltrials |
| NCT00463996 | MRI in Staging Ovarian Cancer Using MRI Contrast Agent | unknown | — | 50 | University of AarhusOTHER | 0 | Apr 20, 2007 | clinicaltrials |
| NCT00327925 | Blood Test for Ovarian Cancer Associated Antibodies (CAAb) | unknown | — | 60 | Lab Discoveries Ltd.INDUSTRY | 1 | Mar 2, 2007 | clinicaltrials |
| NCT00287482 | Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer. | terminated | N/A | 20 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Feb 12, 2007 | clinicaltrials |
| NCT00419627 | Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas | unknown | — | 160 | Hillel Yaffe Medical CenterOTHER_GOV | 1 | Jan 8, 2007 | clinicaltrials |
| NCT00173394 | The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients | unknown | — | 250 | National Taiwan University HospitalOTHER | 1 | Dec 19, 2006 | clinicaltrials |
| NCT00102414 | Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer | completed | Phase 3 | 356 | AGO Study GroupOTHER | 0 | Nov 14, 2006 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00070967 | Acupuncture to Improve Quality of Life in Patients With Advanced Cancer | completed | Phase 2 | 40 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00102375 | Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer | completed | Phase 3 | 900 | AGO Study GroupOTHER | 1 | Aug 4, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00312988 | Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy | completed | Phase 3 | 450 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Apr 11, 2006 | clinicaltrials |
| NCT00155740 | Mesothelin as a New Tumor Marker for Ovarian Cancer | unknown | — | 250 | National Taiwan University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
| NCT00231075 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | completed | Phase 2 | 75 | ARCAGY/ GINECO GROUPOTHER | 1 | Nov 3, 2005 | clinicaltrials |
| NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | terminated | Phase 3 | 300 | AGO Study GroupOTHER | 1 | Sep 19, 2005 | clinicaltrials |
| NCT00154986 | IGFBP-3 in Ovarian Cancer Invasion | unknown | N/A | 30 | National Taiwan University HospitalOTHER | 1 | Sep 12, 2005 | clinicaltrials |
| NCT00155896 | Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer | unknown | — | 100 | National Taiwan University HospitalOTHER | 1 | Sep 12, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jul 15, 2008source: clinicaltrials